Nutrition for Brain and Body Health (BB-Health) Feasibility Trial
NCT ID: NCT05542199
Last Updated: 2025-05-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
25 participants
INTERVENTIONAL
2022-09-13
2024-02-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Preventing Obesity Using Novel Dietary Strategies
NCT00072995
The Retrain Your Brain for Healthy Eating Study
NCT05203718
Effects of Macronutrient Diet on Brain Activity
NCT02300857
A Novel Diet-Phenotype Interaction Affecting Body Weight
NCT01303757
Time Restricted Eating for Metabolic and Psychological Optimization
NCT05997316
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
+MCNS+WL
This group receives the multicomponent nutrition supplement and the behavioral weight loss intervention.
Multicomponent nutrition supplement (MCNS)
Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
Behavioral weight loss program
Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
-MCNS+WL
This group receives the placebo nutrition supplement and the behavioral weight loss intervention.
Behavioral weight loss program
Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
+MCNS-WL
This group receives the multicomponent nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes).
Multicomponent nutrition supplement (MCNS)
Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
-MCNS-WL
This group receives the placebo nutrition supplement and is in the control group for the behavioral weight loss intervention (no behavioral intervention during the trial, but participant is wait-listed to receive one after the trial finishes)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multicomponent nutrition supplement (MCNS)
Palatable daily nutrition supplement for 12 months containing approximately 300 kcal and a wide range of nutrients and plant constituents with potential to support brain health and cognition.
Behavioral weight loss program
Enrollment in behavioral weight loss intervention for 12 months modeled on the Diabetes Prevention Program.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI of 27.0-39.9 kg/m2 at screening (higher BMIs not included at this time to facilitate program adherence);
3. Scores of 34 or greater on the Modified Telephone Interview for Cognitive Status (TICS-M) at screening (85). The purpose of this screen is to ensure that participants can give consent and adhere to the study requirements, including the outcomes testing.
4. Willing to be randomized and participate in all study components, including consuming the foods and supplements, participating in the WL intervention or control meetings, being available for outcome assessments, using the provided home Wi-Fi scale and activity monitor daily, and completing questionnaires, as well as providing the login information for scales and activity monitor so investigators can download the data.
5. Satisfactory screening review of health history questionnaire by nursing staff for relevant factors including no evidence of exclusions listed below. This will include verbal confirmation of completing a course of vaccination against COVID-19 (two doses plus one booster prior to screening visit). The reason for this study component is that live group meetings are planned with other participants, and this will reduce participant risk.
6. Has access to computer or smartphone with Wi-Fi and possesses a freezer at home with space for supplement storage.
7. Rates representative food with characteristics of the MCNS and control foods at least 4 on a 5-point scale of liking at screening, and reports that they are willing to consume the food daily.
8. Average energy intake in 3 24-h dietary recalls is within physiological (i.e., plausible) range.
Exclusion Criteria
2. Regularly taking a multivitamin, cacao/cocoa supplement, choline supplement, DHA/EPA supplement, or any supplement advertised for brain health or cognitive function (\>1/week). Washout period of 2 months accepted.
3. Does not like, or alternatively reports eating \>1 serving per week of \>60% chocolate or cocoa.
4. Severe cardiovascular disease including stroke, heart failure, coronary bypass and valve replacement, coronary bypass or any surgical procedures or signs and symptoms of current severe cardiovascular disease.
5. History of neurological brain disease, including stroke, seizure disorders, traumatic brain injury (moderate to severe); including prior diagnosis of a neurodegenerative disease including AD and Parkinson's disease, frontotemporal dementia. Moderate traumatic brain injury is defined by an injury with loss of consciousness.
6. Major psychiatric disorder history (schizophrenia, bipolar affective disorder, intractable depression).
7. Inadequately controlled hypertension at the discretion of study MD or RN
8. Diabetes Type 1 \& Type 2 or use of any pharmacological treatment for diabetes or HbA1c \>6.5 at screening.
10. History of stomach or bowel resection (other than appendectomy), gastric bypass, or other bariatric weight loss procedure
11. GI diseases, conditions or meds known to influence GI absorption including active peptic ulcer disease or inflammatory bowel disease (such as ulcerative colitis, Crohn's disease), Celiac disease, Cystic Fibrosis, malabsorption disorders, gallbladder disease, acute or chronic pancreatitis or Pancreatic insufficiency
12. Chronic kidney disease or history of kidney stones
13. History of diagnosed eating disorder anorexia, bulimia or binge-eating
14. Active treatment for cancer (except non-melanoma skin cancer) of any type in ≤ 3 year.
15. Thyroid disease or other significant endocrine disorder
16. Uncontrolled hypercholesterolemia.
17. History of acute or chronic pancreatitis or gall bladder disease.
18. Metabolic disorders or conditions that interfere with nutrient absorption (such as Phenylketonuria, Maple Syrup Urine Disease, glucose-galactose malabsorption, ornithine transcarbamylase deficiency or hypophosphatemic rickets.)
19. Dose adjustment to statin or antihypertensive medication within the past 3 months
20. Screening lab results outside the normal parameters that may interfere with study outcomes at the discretion of study MD
21. Inadequate venous access or history of a bilateral mastectomy with nodal dissection
22. Recent history of inflammatory diseases (for example: rheumatoid arthritis, lupus)
23. Active WL, or weight change \> 4 kg in past 6 months.
24. Consuming a restrictive diet (e.g. gluten-free, vegan, Paleolithic diet).
25. Self-reported allergy to any ingredient in the provided intervention foods.
26. Self-reported severe allergy to adhesives.
27. Unwilling to use a mobile phone or computer with videoconference software to participate in intervention group meetings. Unwilling to eat on camera.
28. Reports of consumption of \> 2 alcoholic drinks per day on average or \>14/week (168oz beer/56oz wine/14oz hard liquor.)
29. Reports of consumption of \> 2 cups of green or black tea per day on average.
30. Reports of use of recreational and/or illegal drugs.
31. Regular smoking or vaping tobacco or marijuana including the use of edibles within the last 6 months (greater than once a week)
32. Non-English speakers.
33. No social security number (required for stipend payment).
55 Years
85 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
University of Florida
OTHER
University of New Hampshire
OTHER
Tufts University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susan B. Roberts, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Jean Mayer USDA Human Nutrition Research Center on Aging
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2273
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.